Home / Market News / $UTHR
benzinga Corporate Catalyst Impact 75/100 ● positive

United Therapeutics Announces Publication of ADVANCE OUTCOMES Study in The Lancet; Ralinepag Remains Investigational for PAH

Jul 29, 2026, 10:38 AM UTC · Primary ticker $UTHR

United Therapeutics announced the publication of positive Phase 3 ADVANCE OUTCOMES study results for ralinepag in The Lancet, confirming the drug met its primary and key secondary endpoints for pulmonary arterial hypertension (PAH). This publication validates the drug's efficacy and safety profile, supporting its New Drug Application (NDA) submission to the FDA and potentially paving the way for market approval.

United Therapeutics announced the publication of the full results of its ADVANCE OUTCOMES study for ralinepag in The Lancet. This is a significant event as it validates the positive Phase 3 clinical trial data, showing ralinepag met its primary endpoint by reducing the risk of clinical worsening in PAH patients by 55% and achieved statistically significant improvements in key secondary endpoints. This publication strengthens the drug's profile as it awaits FDA approval, following the NDA submission in June 2026. For UTHR, this news is a strong positive, as it de-risks the drug's path to market and highlights its potential as a once-daily oral prostacyclin receptor agonist for PAH, a chronic and progressive disease. The long-term implication is a potential new revenue stream for United Therapeutics, while the short-term impact could be increased investor confidence and stock price appreciation.

$UTHR positive Positive clinical trial data publication
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.